Search Results 1051-1060 of 16105 for pharmacogenetics
This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy ...
While working as a medical missionary in West Africa for nearly 20 years, Thomas (Tom) D. Thacher developed a research interest in nutritional rickets — a ...
Neuropathy Symptom and Change Score (NSC); Physical component summary (PCS) score of 36-Item Short Form Survey (SF-36); Polyneuropathy disability (PND) score ...
The purpose of this study is to compare loco-regional liposomal bupivacaine injection versus normal saline (placebo control group) to assess possible reduction ...
The purpose of the study is to learn more about autoimmunity and potential mother to baby transmission of pathogenic antibodies.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
It also aimes to evaluate immunosuppression related patient reported outcomes in kidney transplant recipients with type 2 diabetes. Participation eligibility.
D., is a Medical Neuro-Oncologist with special interest in early therapeutics development and novel immunotherapeutic combinations to treat brain tumors. Dr.
Research. As the ethical complexity of medical research and innovation has increased, so, too, has the need to examine patient and professional values ...
This study aims to identify candidate High Grade Serous Cancer (HGSC) early detection and chemotherapy treatment response biomarkers.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Give by Dec. 3 to double your impact 2X.